keyword
MENU ▼
Read by QxMD icon Read
search

radium

keyword
https://www.readbyqxmd.com/read/27912187/holistic-risk-assessment-of-surface-water-contamination-due-to-pb-210-in-oil-produced-water-from-the-bakken-shale
#1
Luisa Torres, Om Prakash Yadav, Eakalak Khan
A holistic risk assessment of surface water (SW) contamination due to lead-210 (Pb-210) in oil produced water (PW) from the Bakken Shale in North Dakota (ND) was conducted. Pb-210 is a relatively long-lived radionuclide and very mobile in water. Because of limited data on Pb-210, a simulation model was developed to determine its concentration based on its parent radium-226 and historical total dissolved solids levels in PW. Scenarios where PW spills could reach SW were analyzed by applying the four steps of the risk assessment process...
November 29, 2016: Chemosphere
https://www.readbyqxmd.com/read/27911459/evaluation-of-bone-metastases-by-18f-choline-pet-ct-in-a-patient-with-castration-resistant-prostate-cancer-treated-with-radium-223
#2
Piera Scalzi, Cinzia Baiocco, Sabrina Genovese, Antonella Trevisan, Zuzana Sirotova, Carlo Poti
BACKGROUND: To date, bone metastases remain the main cause of morbidity and mortality in patients with metastatic castration-resistant prostate cancer (mCRPC). Therefore, the combination of accurate early detection of bony disease and effective treatment of these lesions is crucial in the management of mCRPC patients, but clinical trials specifically designed to test novel approaches are currently lacking. CASE DESCRIPTION: This report describes the case of a 74-year-old male with bone mCRPC and symptomatic and biochemical progression, who underwent radium-223 therapy, following previous treatment failure...
December 2, 2016: Urologia
https://www.readbyqxmd.com/read/27896639/seom-clinical-guideline-for-bone-metastases-from-solid-tumours-2016
#3
C Grávalos, C Rodríguez, A Sabino, M Á Seguí, J A Virizuela, A Carmona, J Cassinello, D Isla, C Jara, M Martín
Bone metastases are common in many advanced solid tumours, being breast, prostate, thyroid, lung, and renal cancer the most prevalent. Bone metastases can produce skeletal-related events (SREs), defined as pathological fracture, spinal cord compression, need of bone irradiation or need of bone surgery, and hypercalcaemia. Patients with bone metastases experience pain, functional impairment and have a negative impact on their quality of life. Several imaging techniques are available for diagnosis of this disease...
December 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27893426/sublethal-exposure-to-alpha-radiation-223ra-dichloride-enhances-various-carcinomas-sensitivity-to-lysis-by-antigen-specific-cytotoxic-t-lymphocytes-through-calreticulin-mediated-immunogenic-modulation
#4
Anthony S Malamas, Sofia R Gameiro, Karin M Knudson, James W Hodge
Radium-223 dichloride (Xofigo®; 223Ra) is an alpha-emitting radiopharmaceutical FDA-approved for the treatment of bone metastases in patients with advanced castration-resistant prostate cancer. It is also being examined clinically in patients with breast and lung carcinoma and patients with multiple myeloma. As with other forms of radiation, the aim of 223Ra is to reduce tumor burden by directly killing tumor cells. External beam (photon) and proton radiation have been shown to augment tumor sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes (CTLs)...
November 23, 2016: Oncotarget
https://www.readbyqxmd.com/read/27887972/radon-as-a-natural-tracer-for-underwater-cave-exploration
#5
Katalin Csondor, Anita Erőss, Ákos Horváth, Dénes Szieberth
The Molnár János cave is one of the largest hypogenic caves of the Buda Thermal Karst (Budapest, Hungary) and mainly characterized by water-filled passages. The major outflow point of the waters of the cave system is the Boltív spring, which feeds the artificial Malom Lake. Previous radon measurements in the cave system and in the spring established the highest radon concentration (71 BqL(-1)) in the springwater. According to previous studies, the origin of radon was identified as iron-hydroxide containing biofilms, which form where there is mixing of cold and thermal waters, and these biofilms efficiently adsorb radium from the thermal water component...
November 22, 2016: Journal of Environmental Radioactivity
https://www.readbyqxmd.com/read/27885457/-psma-targeted-radioligand-therapy-in-prostate-cancer
#6
M M Heck, M Retz, R Tauber, K Knorr, C Kratochwil, M Eiber
Radioligand therapy (RLT) directed against prostate-specific membrane antigen (PSMA) enables tumor-specific treatment directed against PSMA-overexpressing prostate cancer cells. Several PSMA ligands such as PSMA-617 or PSMA-I&T have been developed that can be labeled with β‑radiating lutetium-177. These are currently applied in compassionate use programs to treat metastatic castration-resistant prostate cancer (mCRPC). PSMA-directed RLT is currently being offered in several nuclear medicine departments throughout Germany...
November 24, 2016: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/27885095/remediation-of-radium-legacies-from-the-swiss-watch-industry
#7
Christophe Murith, Sébastien Baechler, Sybille Estier, Martha Palacios-Gruson
Discovery of radioactive radium contaminations in a former landfill site in Biel was made in 2014. Following this, it was decided to search for and remediate sites that had possibly been contaminated with radium as a result of its use in the watchmaking industry between 1920 and 1960. This work describe the general approach to identify survey and remediate affected sites. The methods is based on the concept of existing exposure situations as developed by the International Commission on Radiological Protection, and is supported by an action plan for radium 2015-2019 approved by the Federal Council in 2015...
November 24, 2016: Radiation Protection Dosimetry
https://www.readbyqxmd.com/read/27876504/disease-and-treatment-characteristics-of-men-diagnosed-with-metastatic-hormone-sensitive-prostate-cancer-in-real-life-analysis-from-a-commercial-claims-database
#8
Thomas W Flaig, Ravi C Potluri, Yvette Ng, Mary B Todd, Maneesha Mehra, Celestia S Higano
BACKGROUND: Our understanding of the clinical characteristics and treatment patterns of men who present with newly diagnosed metastatic (M1) hormone-sensitive prostate cancer is based mainly on clinical trial data. We sought to characterize the M1 population seen in routine clinical practice using a commercial claims database. PATIENTS AND METHODS: A US claims (2000-2013) database was used to identify patients with an index diagnosis of prostate cancer. M1 patients were identified by "International Classification of Diseases, 9th revision, Clinical Modification" diagnosis codes of metastasis to bone, viscera, distant lymph node, and unspecified sites within 90 days of the prostate cancer diagnosis...
October 18, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27843540/radium-223-and-metastatic-castration-resistant-prostate-cancer-all-that-glitters-is-not-gold
#9
REVIEW
Carlo Aprile, Marco G Persico, Lorenzo Lodola, Federica E Buroni
After being approved by the National Drug Agency in several countries, Radium-223 (Ra-223) is gaining wide acceptance in the treatment of bone metastatic castration resistant prostate cancer. The exact mechanism of action remain unclear: The established model of direct alpha-particle irradiation from the remodelling bone surface, where Ra-223 accumulates, surrounding the tumor foci can explain a lethal effect only on metastatic microdeposits, but not on higher tumor burden. According to the "pre-metastatic niche model", it is likely that Ra-223 targets several non-tumoral cell types of the tumor microenvironment involved in the complex mechanism of cancer bone homing and colonization...
October 28, 2016: World Journal of Radiology
https://www.readbyqxmd.com/read/27843209/radioisotopes-in-management-of-metastatic-prostate-cancer
#10
REVIEW
Amar Raval, Tu D Dan, Noelle L Williams, Andrew Pridjian, Robert B Den
INTRODUCTION: Metastatic prostate cancer continues to be a leading cause of morbidity and mortality in men with prostate cancer. Over the last decade, the treatment landscape for patients with castrate-resistant disease has drastically changed, with several novel agents demonstrating an improvement in overall survival in large, multi-institutional randomized trials. Traditional treatment with radioisotopes has largely been in the palliative setting. However, the first in class radiopharmaceutical radium-223 has emerged as the only bone-directed treatment option demonstrating an improvement in overall survival...
October 2016: Indian Journal of Urology: IJU: Journal of the Urological Society of India
https://www.readbyqxmd.com/read/27835737/a-radium-223-microgenerator-from-cyclotron-produced-trace-actinium-227
#11
Diane S Abou, Juile Pickett, John E Mattson, Daniel L J Thorek
The alpha particle emitter Radium-223 dichloride ((223)RaCl2) has recently been approved for treatment of late-stage bone metastatic prostate cancer. There is considerable interest in studying this new agent outside of the clinical setting, however the supply of (223)Ra is limited and expensive. We have engineered a (223)Ra microgenerator using traces of (227)Ac previously generated from cyclotron-produced (225)Ac. Radiochemically pure (223)RaCl2 was made, characterized, evaluated in vivo, and the source was recovered in high yield for regeneration of the microgenerator...
January 2017: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/27825713/influence-of-soil-structure-on-the-fv-approach-applied-to-238-u-and-226-ra
#12
P Blanco Rodríguez, F Vera Tomé, J C Lozano
The soil-to-plant transfer factors were determined in a granitic area for the two long-lived uranium series radionuclides (238)U and (226)Ra. With the aim to identify a physical fraction of soil whose concentration correlates linearly with the plant concentration, the soil compartment was analyzed in various stages. An initial study identified the soil compartments as being either bulk soil or its labile fraction. The bulk soil was subsequently divided into three granulometric fractions consisting of: coarse sand, fine sand, and silt and clay...
November 5, 2016: Chemosphere
https://www.readbyqxmd.com/read/27825434/radium-223-therapy-of-bone-metastases-in-prostate-cancer
#13
REVIEW
Sten Nilsson
Metastatic castration-resistant prostate cancer frequently metastasizes to the bone, often resulting in painful skeletal events, reduced quality of life, and reduced survival. Radium-223 is a first-in-class alpha-emitting radiopharmaceutical that has proven to prolong overall survival, delay time to symptomatic skeletal events, and improve quality of life in patients with castration-resistant prostate cancer and symptomatic bone metastases and no visceral metastases. Radium-223 provides survival benefit to patients with castration-resistant prostate cancer and symptomatic bone metastases, regardless of prior docetaxel use...
November 2016: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27822685/sequencing-treatment-for-castration-resistant-prostate-cancer
#14
REVIEW
Catherine E Handy, Emmanuel S Antonarakis
Prostate cancer is the most common non-cutaneous cancer diagnosed in men and the second leading cause of male cancer deaths in the USA. While most cases are diagnosed in early stages, some will present as or progress to metastatic disease and eventually castration-resistant prostate cancer (mCRPC) which has a mortality rate exceeding 50 %. There are currently six approved systemic life-prolonging therapies for use in mCRPC, yet little data to guide sequencing. Clinical factors, including the presence or absence of symptoms and the presence or absence of visceral metastases, should help determine the best therapeutic choice at each treatment node...
December 2016: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/27806616/development-of-a-transmission-alpha-particle-dosimetry-technique-using-a549-cells-and-a-ra-223-source-for-targeted-alpha-therapy
#15
R Al Darwish, A H Staudacher, Y Li, M P Brown, E Bezak
PURPOSE: In targeted radionuclide therapy, regional tumors are targeted with radionuclides delivering therapeutic radiation doses. Targeted alpha therapy (TAT) is of particular interest due to its ability to deliver alpha particles of high linear energy transfer within the confines of the tumor. However, there is a lack of data related to alpha particle distribution in TAT. These data are required to more accurately estimate the absorbed dose on a cellular level. As a result, there is a need for a dosimeter that can estimate, or better yet determine the absorbed dose deposited by alpha particles in cells...
November 2016: Medical Physics
https://www.readbyqxmd.com/read/27800631/meeting-report-from-the-prostate-cancer-foundation-scientific-working-group-on-radium-223
#16
REVIEW
Andrea K Miyahira, Michael Morris, Howard R Soule
INTRODUCTION: The Prostate Cancer Foundation (PCF) convened a Scientific Working Group Meeting on Radium-223 on September 8, 2016, at The Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center. METHODS: The meeting was attended by 18 investigators with expertise in radium-223, bone biology, molecular imaging, biomarkers, and prostate cancer clinical trials. The goal of this meeting was to discuss the known and unknown surroundings the therapeutic effects of the bone targeting agent radium-223, in bone metastatic prostate cancer therapy, and to outline the most critical studies needed to improve the clinical use of this agent...
November 1, 2016: Prostate
https://www.readbyqxmd.com/read/27796762/new-biomarkers-for-selecting-the-best-therapy-regimens-in-metastatic-castration-resistant-prostate-cancer
#17
Isabel Heidegger, Axel Heidenreich, David Pfister
Prostate cancer is the most common cancer in men. In recent years, several new targeted therapeutic agents for the treatment of metastatic castration resistant prostate cancer (mCRPC) have been developed. These include androgen receptor targeting agents, new taxanes, radium-223, and immunotherapies. In this short review, we provide a summary of clinical and preclinical biomarkers for each of these new treatment strategies, also including new markers currently presented in conference papers only. Moreover, we address the role of these biomarkers in clinical routine with the aim to select best-personalized treatment strategies for patients...
October 27, 2016: Targeted Oncology
https://www.readbyqxmd.com/read/27793893/radium-223-insight-and-perspectives-in-bone-metastatic-castration-resistant-prostate-cancer
#18
REVIEW
Federica Eleonora Buroni, Marco Giovanni Persico, Francesca Pasi, Lorenzo Lodola, Rosanna Nano, Carlo Aprile
(223)Ra prolongs overall survival in symptomatic patients affected by multiple bone-metastatic castration-resistant prostatic cancer, without visceral or nodal involvement. However, many questions remain about its mechanisms of action, and its use in clinical practice is still unresolved. First of all, what is the main target of alpha-particle emission, that is, in what way does it influences the tumor microenvironment? When is the best timing in the course of the disease, extending its use to asymptomatic low-volume or even to the micrometastatic phase? What are suitable biomarkers to be employed as prognostic factors and response indicators? Which associations with other drugs and their sequence can offer the best results, and is their effect additive or synergistic? Ultimately, in the current climate of spending review, what is the optimal cost and benefit ratio regarding available treatments? In this review, we tried to answer these questions by analyzing the available scientific literature...
November 2016: Anticancer Research
https://www.readbyqxmd.com/read/27792921/lower-thresholds-for-lifetime-health-effects-in-mammals-from-high-let-radiation-comparison-with-chronic-low-let-radiation
#19
Tatiana G Sazykina, Alexander I Kryshev
Lower threshold dose rates and confidence limits are quantified for lifetime radiation effects in mammalian animals from internally deposited alpha-emitting radionuclides. Extensive datasets on effects from internal alpha-emitters are compiled from the International Radiobiological Archives. In total, the compiled database includes 257 records, which are analyzed by means of non-parametric order statistics. The generic lower threshold for alpha-emitters in mammalian animals (combined datasets) is 6.6·10(-5) Gy day(-1)...
December 2016: Journal of Environmental Radioactivity
https://www.readbyqxmd.com/read/27774318/radium-223-therapy-for-patients-with-metastatic-castrate-resistant-prostate-cancer-an-update-on-literature-with-case-presentation
#20
Nghi C Nguyen, Muhammad Shah, Leonard J Appleman, Rahul Parikh, James M Mountz
Background and Purpose. Radium-223 dichloride (Xofigo®, Bayer HealthCare Pharmaceuticals Inc.) is the first α-particle emitter therapeutic agent approved by the FDA, with benefits in overall survival and delay in symptomatic skeletal event for patients with metastatic castrate-resistant prostate cancer (CRPC). Recent post hoc analyses of the phase III ALSYMPCA trial support the previously established safety profile as well as therapeutic effect and clinical outcome of Radium-223. Currently, Radium-223 is approved as a single agent therapy for metastatic CRPC...
2016: International Journal of Molecular Imaging
keyword
keyword
30748
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"